Drug development in higher-risk myelodysplastic syndromes

被引:0
|
作者
Venugopal, Sangeetha [1 ]
Sekeres, Mikkael A. [1 ]
机构
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol, Miami, FL 33146 USA
来源
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词
D O I
10.1038/s41408-024-01171-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:3
相关论文
共 50 条
  • [41] An Update on Higher Risk Myelodysplastic Syndromes
    Hochman, Michael J.
    DeZern, Amy E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S21 - S25
  • [42] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [43] Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
    Zeidan, Amer M.
    Platzbecker, Uwe
    Bewersdorf, Jan Philipp
    Stahl, Maximilian
    Ades, Lionel
    Borate, Uma
    Bowen, David
    Buckstein, Rena
    Brunner, Andrew
    Carraway, Hetty E.
    Daver, Naval
    Diez-Campelo, Maria
    de Witte, Theo
    DeZern, Amy E.
    Efficace, Fabio
    Garcia-Manero, Guillermo
    Garcia, Jacqueline S.
    Germing, Ulrich
    Giagounidis, Aristoteles
    Griffiths, Elizabeth A.
    Hasserjian, Robert P.
    Hellstrom-Lindberg, Eva
    Iastrebner, Marcelo
    Komrokji, Rami
    Kulasekararaj, Austin G.
    Malcovati, Luca
    Miyazaki, Yasushi
    Odenike, Olatoyosi
    Santini, Valeria
    Sanz, Guillermo
    Scheinberg, Phillip
    Stauder, Reinhard
    van de Loosdrecht, Arjan A.
    Wei, Andrew H.
    Sekeres, Mikkael A.
    Fenaux, Pierre
    BLOOD, 2023, 141 (17) : 2047 - 2061
  • [44] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
  • [45] Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
    Zeidan, Amer M.
    Divino, Victoria
    DeKoven, Mitch
    Shah, Drishti
    Wang, Elizabeth
    Bey, Dawn
    Salimi, Tehseen
    Epstein, Robert S.
    BLOOD, 2021, 138
  • [46] Patient, Caregiver, and Physician Perspectives on Communication in Diagnosing and Treating Higher-Risk Myelodysplastic Syndromes: A Qualitative Study
    Maravic, Melissa Culhane
    Land, Natalie
    Prood, Nadya
    Birch, Kelly
    Cagle, Claire
    May, Suepattra G.
    Sabate, Eduardo J.
    Afulezi, Ngozi
    Jhaveri, Teraneh Z.
    Chen, Mindy
    Hassan, Audrey
    Sadek, Islam
    Hogea, Cosmina
    BLOOD, 2023, 142
  • [47] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [48] Higher-risk myelodysplastic syndromes. Does the severity of cytopenias at diagnosis have any prognostic significance?
    Calderon, C.
    Falantes, J. F.
    Marquez, F. J.
    Martino, M. L.
    Gonzalez, J.
    Montero, M. I.
    Parody, R.
    Espigado, I.
    Perez-Simon, J. A.
    LEUKEMIA RESEARCH, 2013, 37 : S83 - S83
  • [49] Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 49 - 56
  • [50] Machine Learning Approach to Understand Real-World Treatment in Patients with Higher-Risk Myelodysplastic Syndromes
    Priya, Vandana
    Vaidya, Vivek P.
    Agrawal, Smita
    Singh, Neeraj
    Chatra, Kaveri
    Parmar, Dhaval
    Yan, Raymond
    Das, Rahul K.
    Haririfar, Mahnoush
    McMahon, Peter
    Williamson, Mellissa
    Sadek, Islam
    Hogea, Cosmina
    BLOOD, 2023, 142